Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 208

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study

Open access
Duong, MyLinh, Islam, Shofiqul, Rangarajan, Sumathy, Leong, Darryl, Kurmi, Om, Teo, Koon, Killian, Kieran, Dagenais, Gilles, Lear, Scott, Wielgosz, Andreas, Nair, Sanjeev, Mohan, Viswanathan, Mony, Prem, Gupta, Rajeev, Kumar, Rajesh, Rahman, Omar, Yusoff, Khalid, du Plessis, Johannes Lodewykus, Igumbor, Ehimario U, Chifamba, Jephat, Li, Wei, Lu, Yin, Zhi, Fumin, Yan, Ruohua, Iqbal, Romaina, Ismail, Noorhassim, Zatonska, Katarzyna, Karsidag, Kubilay, Rosengren, Annika, Bahonar, Ahmad, Yusufali, Afazalhussein, Lamelas, Pablo M, Avezum, Alvaro, Lopez-Jaramillo, Patricio, Lanas, Fernando, O'Byrne, Paul M, Yusuf, Salim · 2019 · The Lancet Global Health

Abstract

Background The associations between the extent of forced expiratory volume in 1 s (FEV 1 ) impairment and mortality, incident cardiovascular disease, and respiratory hospitalisations are unclear, and how these associations might vary across populations is unknown. Methods In this international, community-based cohort study, we prospectively enrolled adults aged 35–70 years who had no intention of moving residences for 4 years from rural and urban communities across 17 countries. A portable spirometer was used to assess FEV 1 . FEV 1 values were standardised within countries for height, age, and sex, and expressed as a percentage of the country-specific predicted FEV 1 value (FEV 1 %). FEV 1 % was categorised as no impairment (FEV 1 % ≥0 SD from country-specific mean), mild impairment (FEV 1 % <0 SD to −1 SD), moderate impairment (FEV 1 % <–1 SD to −2 SDs), and severe impairment (FEV 1 % <–2 SDs [ie, clinically abnormal range]). Follow-up was done every 3 years to collect information on mortality, cardiovascular disease outcomes (including myocardial infarction, stroke, sudden death, or congestive heart failure), and respiratory hospitalisations (from chronic obstructive pulmonary disease, asthma, pneumonia, tuberculosis, or other pulmonary conditions). Fully adjusted hazard ratios (HRs) were calculated by multilevel Cox regression. Findings Among 126 359 adults with acceptable spirometry data available, during a median 7·8 years (IQR 5·6–9·5) of follow-up, 5488 (4·3%) deaths, 5734 (4·5%) cardiovascular disease events, and 1948 (1·5%) respiratory hospitalisation events occurred. Relative to the no impairment group, mild to severe FEV 1 % impairments were associated with graded increases in mortality (HR 1·27 [95% CI 1·18–1·36] for mild, 1·74 [1·60–1·90] for moderate, and 2·54 [2·26–2·86] for severe impairment), cardiovascular disease (1·18 [1·10–1·26], 1·39 [1·28–1·51], 2·02 [1·75–2·32]), and respiratory hospitalisation (1·39 [1·24–1·56], 2·02 [1·75–2·32], 2·97 [2·45–3·60]), and this pattern persisted in subgroup analyses considering country income level and various baseline risk factors. Population-attributable risk for mortality (adjusted for age, sex, and country income) from mildly to moderately reduced FEV 1 % (24·7% [22·2–27·2]) was larger than that from severely reduced FEV 1 % (3·7% [2·1–5·2]) and from tobacco use (19·7% [17·2–22·3]), previous cardiovascular disease (5·5% [4·5–6·5]), and hypertension (17·1% [14·6–19·6]). Population-attributable risk for cardiovascular disease from mildly to moderately reduced FEV 1 was 17·3% (14·8–19·7), second only to the contribution of hypertension (30·1% [27·6–32·5]). Interpretation FEV 1 is an independent and generalisable predictor of mortality, cardiovascular disease, and respiratory hospitalisation, even across the clinically normal range (mild to moderate impairment). Funding Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Ontario Ministry of Health and Long-Term Care, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Servier, and GlaxoSmithKline, Novartis, and King Pharma. Additional funders are listed in the appendix.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2214-109x(19)30070-1

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 208

Metadata

Authors
Duong, M., Islam, S., Rangarajan, S., Leong, D., Kurmi, O., Teo, K., Killian, K., Dagenais, G., Lear, S., Wielgosz, A., Nair, S., Mohan, V., Mony, P., Gupta, R., Kumar, R., Rahman, O., Yusoff, K., du Plessis, J. L., Igumbor, E. U., Chifamba, J., Li, W., Lu, Y., Zhi, F., Yan, R., Iqbal, R., Ismail, N., Zatonska, K., Karsidag, K., Rosengren, A., Bahonar, A., Yusufali, A., Lamelas, P. M., Avezum, A., Lopez-Jaramillo, P., Lanas, F., O'Byrne, P. M., & Yusuf, S.
Venue
The Lancet Global Health
Publisher
Elsevier BV
Published
2019-05
Volume
7
Issue
5
Pages
e613-e623
ISSN
2214-109X (ISSN-L)
OpenAlex
W2938704617
Cited by
208
References
4
FWCI
13.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. https://app.cochat.ai/papers/10.1016/s2214-109x(19)30070-1
The paper
Duong, M., Islam, S., Rangarajan, S., Leong, D., Kurmi, O., Teo, K., Killian, K., Dagenais, G., Lear, S., Wielgosz, A., Nair, S., Mohan, V., Mony, P., Gupta, R., Kumar, R., Rahman, O., Yusoff, K., du Plessis, J. L., Igumbor, E. U., . . . Yusuf, S. (2019). Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(19)30070-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.